Skip to main content
SpringerLink
Log in

Molecular Pathogenesis of Uterine Fibroids

  • Chapter
  • First Online:
Uterine Fibroids and Adenomyosis

Part of the book series: Comprehensive Gynecology and Obstetrics ((CGO))

  • 983 Accesses

Abstract

Researchers investigated aberrant gene expression in uterine fibroids to elucidate their molecular pathogenesis. Complex networks of multiple factors such as growth factors and WNT/β-catenin signaling have been shown to be involved in the pathogenesis of uterine fibroids. This chapter will focus on the current knowledge of molecular mechanism that are involved in the generation or development of uterine leiomyomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chang HL, Senaratne TN, Zhang L, Szotek PP, Stewart E, Dombkowski D, Preffer F, Donahoe PK, Teixeira J. Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium. Reprod Sci. 2010;17:158–67.

    Article  PubMed  Google Scholar 

  2. Ono M, Maruyama T, Masuda H, Kajitani T, Nagashima T, Arase T, Ito M, Ohta K, Uchida H, Asada H, Yoshimura Y, Okano H, Matsuzaki Y. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci U S A. 2007;104:18700–5.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Galvez BG, Martín NS, Salama-Cohen P, Lazcano JJ, Coronado MJ, Lamelas ML, Alvarez-Barrientes A, Eiró N, Vizoso F, Rodríguez C. An adult myometrial pluripotential precursor that promotes healing of damaged muscular tissues. In Vivo. 2010;24:431–41.

    PubMed  CAS  Google Scholar 

  4. Zhou S, Yi T, Shen K, Zhang B, Huang F, Zhao X. Hypoxia: the driving force of uterine myometrial stem cells differentiation into leiomyoma cells. Med Hypotheses. 2011;77(6):985.

    Article  PubMed  Google Scholar 

  5. Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK, Teixeira J. Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol. 2005;288:276–83.

    Article  PubMed  CAS  Google Scholar 

  6. Szotek PP, Chang HL, Zhang L, Preffer F, Dombkowski D, Donahoe PK, Teixeira J. Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation. Stem Cells. 2007;25:1317–25.

    Article  PubMed  CAS  Google Scholar 

  7. Ono M, Qiang W, Serna VA, Yin P, Coon JS V, Navarro A, Monsivais D, Kakinuma T, Dyson M, Druschitz S, Unno K, Kurita T, Bulun SE. Role of stem cells in human uterine leiomyoma growth. PLoS One. 2012;7:e36935.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Hodge JC, Kim TM, Dreyfuss JM, Somasundaram P, Christacos NC, Rousselle M, Quade BJ, Park PJ, Stewart EA, Morton CC. Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profiling of the t(12;14) and evidence in support of predisposing genetic heterogeneity. Hum Mol Genet. 2012;21:2312–29.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Markowski DN, Helmke BM, Belge G, Nimzyk R, Bartnitzke S, Deichert U, Bullerdiek J. HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications. Anticancer Res. 2011;31:753–61.

    PubMed  Google Scholar 

  10. Peng Y, Laser J, Shi G, et al. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res. 2008;6:663–73.

    Article  PubMed  CAS  Google Scholar 

  11. Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P, Wei JJ. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334:252–5.

    Article  CAS  Google Scholar 

  12. Pérot G, Croce S, Ribeiro A, et al. MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One. 2012;7(6):e40015.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Ravegnini G, Mariño-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, Nucci MR, George S, Angelini S, Raut CP, Fletcher JA. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol. 2013;26:743–9.

    Article  PubMed  CAS  Google Scholar 

  14. Hammond SM, Sharpless NE. HMGA2, microRNAs, and stem cell aging. Cell. 2008;135(6):1013.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Bulun SE. Uterine fibroids. N Engl J Med. 2013;369:1344–55.

    Article  PubMed  CAS  Google Scholar 

  16. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One. 2012;7:e33251.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Markowski DN, Bartnitzke S, Löning T, Drieschner N, Helmke BM, Bullerdiek J. MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups. Int J Cancer. 2012;131:1528–36.

    Article  PubMed  CAS  Google Scholar 

  18. Kim S, Xu X, Hecht A, Boyer TG. Mediator is a transducer of Wnt/beta-catenin signaling. J Biol Chem. 2006;281:14066–75.

    Article  PubMed  CAS  Google Scholar 

  19. Rocha PP, Scholze M, Bleiss W, Schrewe H. Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. Development. 2010;137:2723–31.

    Article  PubMed  CAS  Google Scholar 

  20. Lin X, Rinaldo L, Fazly AF, Xu X. Depletion of Med10 enhances Wnt and suppresses Nodal signaling during zebrafish embryogenesis. Dev Biol. 2007;303:536–48.

    Article  PubMed  CAS  Google Scholar 

  21. Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, Neefjes J, Salazar R, Ten Dijke P, Uramoto H, Tanaka F, Beijersbergen RL, Wessels LF, Bernards R. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell. 2012;151:937–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Guo X, Wang XF. A mediator lost in the war on cancer. Cell. 2012;151:927–9.

    Article  PubMed  CAS  Google Scholar 

  23. Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab. 2001;86:913–20.

    PubMed  CAS  Google Scholar 

  24. Al-Hendy A, Laknaur A, Diamond MP, Ismail N, Boyer TG, Halder SK. Silencing Med12 gene reduces proliferation of human leiomyoma cells mediated via Wnt/β-catenin signaling pathway. Endocrinology. 2017;158:592–603.

    PubMed  Google Scholar 

  25. Marsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstet Gynecol Clin N Am. 2006;33:59–67.

    Article  Google Scholar 

  26. Bulun SE, Simpson ER, Word RA. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture. J Clin Endocrinol Metab. 1994;78:736–43.

    PubMed  CAS  Google Scholar 

  27. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 2004;10:207–20.

    Article  PubMed  CAS  Google Scholar 

  28. Borahay MA, Al-Hendy A, Kilic GS, Boehning D. Signaling pathways in leiomyoma: understanding pathobiology and implications for therapy. Mol Med. 2015;21:242–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34:130–62.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1990;163:1114–9.

    Article  PubMed  CAS  Google Scholar 

  31. Schlaff WD, Zerhouni EA, Huth JA, Chen J, Damewood MD, Rock JA. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol. 1989;74:856–62.

    PubMed  CAS  Google Scholar 

  32. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 1992;166:746–51.

    Article  PubMed  CAS  Google Scholar 

  33. Levin ER. Extranuclear steroid receptors are essential for steroid hormone actions. Annu Rev Med. 2015;66:271–80.

    Article  PubMed  CAS  Google Scholar 

  34. Soltysik K, Czekaj P. Membrane estrogen receptors—is it an alternative way of estrogen action? J Physiol Pharmacol. 2013;64(2):129–42.

    PubMed  CAS  Google Scholar 

  35. Fox EM, Andrade J, Shupnik MA. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids. 2009;74:622–7.

    Article  PubMed  CAS  Google Scholar 

  36. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116:561–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Menasce LP, White GR, Harrison CJ, Boyle JM. Localization of the estrogen receptor locus(ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics. 1993;17:263–5.

    Article  PubMed  CAS  Google Scholar 

  38. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjöld M, Gustafsson JA. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997;82:4258–65.

    PubMed  CAS  Google Scholar 

  39. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863–70.

    Article  PubMed  CAS  Google Scholar 

  40. Dechering K, Boersma C, Mosselman S. Estrogen receptors alpha and beta: two receptors of a kind. Curr Med Chem. 2000;7:561–76.

    Article  PubMed  CAS  Google Scholar 

  41. Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv. 2003;3:281–92.

    Article  PubMed  CAS  Google Scholar 

  42. Smith AW, Rønnekleiv OK, Kelly MJ. Gq-mER signaling has opposite effects on hypothalamic orexigenic and anorexigenic neurons. Steroids. 2014;81:31–5.

    Article  PubMed  CAS  Google Scholar 

  43. Ishikawa H, Reierstad S, Demura M, Rademaker AW, Kasai T, Inoue M, Usui H, Shozu M, Bulun SE. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab. 2009;94:1752–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Sumitani H, Shozu M, Segawa T, Murakami K, Yang HJ, Shimada K, Inoue M. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology. 2000;141:3852–61.

    Article  PubMed  CAS  Google Scholar 

  45. Kasai T, Shozu M, Murakami K, Segawa T, Shinohara K, Nomura K, Inoue M. Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma. J Clin Endocrinol Metab. 2004;89:5661–8.

    Article  PubMed  CAS  Google Scholar 

  46. Bulun SE, Imir G, Utsunomiya H, Thung S, Gurates B, Tamura M, Lin Z. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol. 2005;95:57–62.

    Article  PubMed  CAS  Google Scholar 

  47. Benassayag C, Leroy MJ, Rigourd V, Robert B, Honoré JC, Mignot TM, Vacher-Lavenu MC, Chapron C, Ferré F. Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Phys. 1999;276:E1112–8.

    CAS  Google Scholar 

  48. Kovacs KA, Oszter A, Gocze PM, Kornyei JL, Szabo I. Comparative analysis of cyclin D1 and oestrogen receptor (alpha and beta) levels in human leiomyoma and adjacent myometrium. Mol Hum Reprod. 2001;7:1085–91.

    Article  PubMed  CAS  Google Scholar 

  49. Tian R, Wang Z, Shi Z, Li D, Wang Y, Zhu Y, Lin W, Gui Y, Zheng XL. Differential expression of G-protein coupled estrogen receptor-30 in human myometrial and uterine leiomyoma smooth muscle. Fertil Steril. 2013;99:256–63.

    Article  PubMed  CAS  Google Scholar 

  50. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308:1589–92.

    Article  PubMed  CAS  Google Scholar 

  51. Maekawa R, Sato S, Yamagata Y, Asada H, Tamura I, Lee L, Okada M, Tamura H, Takaki E, Nakai A, Sugino N. Genome-wide DNA methylation analysis reveals a potential mechanism for the pathogenesis and development of uterine leiomyomas. PLoS One. 2013;8:e66632.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Huang PC, Li WF, Liao PC, Sun CW, Tsai EM, Wang SL. Risk for estrogen-dependent diseases in relation to phthalate exposure and polymorphisms of CYP17A1 and estrogen receptor genes. Environ Sci Pollut Res Int. 2014;21:13964–73.

    Article  PubMed  CAS  Google Scholar 

  53. Hsieh YY, Wang YK, Chang CC, Lin CS. Estrogen receptor alpha-351 XbaI*G and -397 PvuII*C-related genotypes and alleles are associated with higher susceptibilities of endometriosis and leiomyoma. Mol Hum Reprod. 2007;13:117–22.

    Article  PubMed  CAS  Google Scholar 

  54. Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Kado N, Tsukamoto K, Hasegawa G, Nakamura N, Honjo H. Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum Reprod. 2001;16:51–5.

    Article  PubMed  CAS  Google Scholar 

  55. Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151:2433–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Hassan MH, Salama SA, Arafa HM, Hamada FM, Al-Hendy A. Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J Clin Endocrinol Metab. 2007;92:3949–57.

    Article  PubMed  CAS  Google Scholar 

  57. Barbarisi A, Petillo O, Di Lieto A, Melone MA, Margarucci S, Cannas M, Peluso G. 17-beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J Cell Physiol. 2001;186:414–24.

    Article  PubMed  CAS  Google Scholar 

  58. Nierth-Simpson EN, Martin MM, Chiang TC, Melnik LI, Rhodes LV, Muir SE, Burow ME, McLachlan JA. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. Endocrinology. 2009;150:2436–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Farber M, Conrad S, Heinrichs WL, Herrmann WL. Estradiol binding by fibroid tumors and normal myometrium. Obstet Gynecol. 1972;40:479–86.

    PubMed  CAS  Google Scholar 

  60. Puukka MJ, Kontula KK, Kauppila AJ, Janne OA, Vihko RK. Estrogen receptor in human myoma tissue. Mol Cell Endocrinol. 1976;6:35–44.

    Article  PubMed  CAS  Google Scholar 

  61. Kim JJ, Sefton EC, Bulun SE. Progesterone receptor action in leiomyoma and endometrial cancer. Prog Mol Biol Transl Sci. 2009;87:53–85.

    Article  PubMed  CAS  Google Scholar 

  62. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol. 1989;160:637–41.

    Article  PubMed  CAS  Google Scholar 

  63. Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL. Progesterone receptor A and B protein expression in human breast cancer. J Steroid Biochem Mol Biol. 1996;56:93–8.

    Article  PubMed  CAS  Google Scholar 

  64. Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids. 2000;65:571–7.

    Article  PubMed  CAS  Google Scholar 

  65. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P. Two distinct estrogen regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990;9:1603–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Zhu Y, Bond J, Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci U S A. 2003;100:2237–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Dressing GE, Goldberg JE, Charles NJ, Schwertfeger KL, Lange CA. Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications. Steroids. 2011;76:11–7.

    Article  PubMed  CAS  Google Scholar 

  68. Yamada T, Nakago S, Kurachi O, Wang J, Takekida S, Matsuo H, Maruo T. Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum Reprod. 2004;19:815–21.

    Article  PubMed  CAS  Google Scholar 

  69. Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab. 1998;83:2192–8.

    PubMed  CAS  Google Scholar 

  70. Maruo T, Matsuo H, Shimomura Y, Kurachi O, Gao Z, Nakago S, Yamada T, Chen W, Wang J. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids. 2000;65:585–92.

    Article  PubMed  CAS  Google Scholar 

  71. Hoekstra AV, Sefton EC, Berry E, Lu Z, Hardt J, Marsh E, Yin P, Clardy J, Chakravarti D, Bulun S, Kim JJ. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab. 2009;94:1768–74.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, Terrill P, Osterloh I, Loumaye E, PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–20.

    Article  PubMed  CAS  Google Scholar 

  73. Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B, Chouaib S. Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol. 2015;309:C569–79.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47.

    Article  PubMed  CAS  Google Scholar 

  75. Tal R, Segars JH. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum Reprod Update. 2014;20:194–216.

    Article  PubMed  CAS  Google Scholar 

  76. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29:625–34.

    Article  PubMed  CAS  Google Scholar 

  77. Deng W, Feng X, Li X, Wang D, Sun L. Hypoxia-inducible factor 1 in autoimmune diseases. Cell Immunol. 2016;303:7–15.

    Article  PubMed  CAS  Google Scholar 

  78. Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology. 2014;143:512–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–32.

    Article  PubMed  CAS  Google Scholar 

  80. Matsumura A, Kubota T, Taiyoh H, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Kokuba Y, Nakamura T, Matsumoto K, Otsuji E. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. Int J Oncol. 2013;42:535–42.

    Article  PubMed  CAS  Google Scholar 

  81. Lin YM, Huang YL, Fong YC, Tsai CH, Chou MC, Tang CH. Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-Met receptor pathway. PLoS One. 2012;7:e50924.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12:9–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. Cramer SF, Mann L, Calianese E, Daley J, Williamson K. Association of seedling myomas with myometrial hyperplasia. Hum Pathol. 2009;40:218–25.

    Article  PubMed  Google Scholar 

  84. Shynlova O, Oldenhof A, Dorogin A, Xu Q, Mu J, Nashman N, Lye SJ. Myometrial apoptosis: activation of the caspase cascade in the pregnant rat myometrium at midgestation. Biol Reprod. 2006;74:839–49.

    Article  PubMed  CAS  Google Scholar 

  85. Shynlova O, Dorogin A, Lye SJ. Stretch-induced uterine myocyte differentiation during rat pregnancy: involvement of caspase activation. Biol Reprod. 2010;82:1248–55.

    Article  PubMed  CAS  Google Scholar 

  86. Mayer A, Hockel M, Wree A, Leo C, Horn LC, Vaupel P. Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. Cancer Res. 2008;68:4719–26.

    Article  PubMed  CAS  Google Scholar 

  87. Mayer A, Hoeckel M, von Wallbrunn A, Horn LC, Wree A, Vaupel P. HIF-mediated hypoxic response is missing in severely hypoxic uterine leiomyomas. Adv Exp Med Biol. 2010;662:399–405.

    Article  PubMed  CAS  Google Scholar 

  88. Uluer ET, Inan S, Ozbilgin K, Karaca F, Dicle N, Sancı M. The role of hypoxia related angiogenesis in uterine smooth muscle tumors. Biotech Histochem. 2015;90:102–10.

    Article  PubMed  CAS  Google Scholar 

  89. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485–90.

    Article  PubMed  CAS  Google Scholar 

  90. Guri Y, Hall MN. mTOR signaling confers resistance to targeted cancer drugs. Trends Cancer. 2016;2:688–97.

    Article  PubMed  Google Scholar 

  91. Showkat M, Beigh MA, Andrabi KI. mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions. Mol Biol Int. 2014;2014:686984.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxia inducible factor 1 alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004–701.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep. 2015;42:841–51.

    Article  PubMed  CAS  Google Scholar 

  94. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem. 2008;283:34495–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Dhingra S, Rodriguez ME, Shen Q, Duan X, Stanton ML, Chen L, Zhang R, Brown RE. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications. Int J Clin Exp Pathol. 2011;4:134–46.

    CAS  Google Scholar 

  96. Sperandio S, Fortin J, Sasik R, Robitaille L, Corbeil J, de Belle I. The transcription factor Egr1 regulates the HIF-1alpha gene during hypoxia. Mol Carcinog. 2009;48:38–44.

    Article  PubMed  CAS  Google Scholar 

  97. Yan SF, Lu J, Zou YS, Soh-Won J, Cohen DM, Buttrick PM, Cooper DR, Steinberg SF, Mackman N, Pinsky DJ, et al. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem. 1999;274:15030–40.

    Article  PubMed  CAS  Google Scholar 

  98. Lucerna M, Mechtcheriakova D, Kadl A, Schabbauer G, Schafer R, Gruber F, Koshelnick Y, Muller HD, Issbrucker K, Clauss M, et al. NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells. J Biol Chem. 2003;278:11433–40.

    Article  PubMed  CAS  Google Scholar 

  99. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med. 2003;9:1026–32.

    Article  PubMed  CAS  Google Scholar 

  100. Pambuccian CA, Oprea GM, Lakatua DJ. Reduced expression of early growth response-1 gene in leiomyoma as identified by mRNA differential display. Gynecol Oncol. 2002;84:431–6.

    Article  PubMed  CAS  Google Scholar 

  101. Shozu M, Murakami K, Segawa T, Kasai T, Ishikawa H, Shinohara K, Okada M, Inoue M. Decreased expression of early growth response-1 and its role in uterine leiomyoma growth. Cancer Res. 2004;64:4677–84.

    Article  PubMed  CAS  Google Scholar 

  102. Ciarmela P, Islam MS, Reis FM, Gray PC, Bloise E, Petraglia F, Vale W, Castellucci M. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update. 2011;17:772–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5):pii: a021873.

    Article  CAS  Google Scholar 

  104. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.

    Article  PubMed  CAS  Google Scholar 

  105. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol. 2005;23:2078–93.

    Article  PubMed  CAS  Google Scholar 

  106. Dou Q, Zhao Y, Tarnuzzer RW, Rong H, Williams RS, Schultz GS, Chegini N. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab. 1996;81:3222–30.

    PubMed  CAS  Google Scholar 

  107. Di X, Andrews DM, Tucker CJ, Yu L, Moore AB, Zheng X, Castro L, Hermon T, Xiao H, Dixon D. A high concentration of genistein down-regulates activin A, Smad3 and other TGF-β pathway genes in human uterine leiomyoma cells. Exp Mol Med. 2012;44:281–92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. Chegini N, Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol. 2003;209:9–16.

    Article  PubMed  CAS  Google Scholar 

  109. Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000;73:1006–11.

    Article  PubMed  CAS  Google Scholar 

  110. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab. 2004;89:5549–57.

    Article  PubMed  CAS  Google Scholar 

  111. Norian JM, Malik M, Parker CY, Joseph D, Leppert PC, Segars JH, Catherino WH. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci. 2009;16:1153–64.

    Article  PubMed  CAS  Google Scholar 

  112. Malik M, Webb J, Catherino WH. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol. 2008;69:462–70.

    Article  CAS  Google Scholar 

  113. Wang J, Ohara N, Wang Z, Chen W, Morikawa A, Sasaki H, DeManno DA, Chwalisz K, Maruo T. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod. 2006;21:1869–77.

    Article  PubMed  CAS  Google Scholar 

  114. Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues, ‘add-back’ steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod. 2002;8:1071–8.

    Article  PubMed  CAS  Google Scholar 

  115. Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int. 2015;2015:538019.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  116. Gkioka E, Msaouel P, Philippou A, Vlaghogiannis NI, Vogkou CT, Margiolis A, Koutsilieris M. Review: the role of insulin-like growth factor-1 signaling pathways in uterine leiomyoma. In Vivo. 2015;29:637–49.

    PubMed  CAS  Google Scholar 

  117. Bach LA. Insulin-like growth factor binding proteins—an update. Pediatr Endocrinol Rev. 2015;13:521–30.

    PubMed  Google Scholar 

  118. Englund K, Lindblom B, Carlström K, Gustavsson I, Sjöblom P, Blanck A. Gene expression and tissue concentrations of IGFI in human myometrium and fibroids under different hormonal conditions. Mol Hum Reprod. 2000;6:915–20.

    Article  PubMed  CAS  Google Scholar 

  119. Zhao Y, Zhang W, Wang S. The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. Gynecol Endocrinol. 2008;24:549–54.

    Article  PubMed  CAS  Google Scholar 

  120. Peng L, Wen Y, Han Y, Wei A, Shi G, Mizuguchi M, Lee P, Hernando E, Mittal K, Wei JJ. Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. Fertil Steril. 2009;91:2664–75.

    Article  PubMed  CAS  Google Scholar 

  121. Dixon D, He H, Haseman JK. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect. 2000;108:795–802.

    Article  PubMed  CAS  Google Scholar 

  122. Van der Ven LT, Roholl PJ, Gloudemans T, Van Buul-Offers SC, Welters MJ, Bladergroen BA, Faber JA, Sussenbach JS, Den Otter W. Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. Br J Cancer. 1997;75:1631–40.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Giudice LC, Irwin JC, Dsupin BA, Pannier EM, Jin IH, Vu TH, Hoffman AR. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod. 1993;8:1796–806.

    Article  PubMed  CAS  Google Scholar 

  124. Burroughs KD, Howe SR, Okubo Y, Fuchs-Young R, LeRoith D, Walker CL. Dysregulation of IGF-I signaling in uterine leiomyoma. J Endocrinol. 2002;172:83–93.

    Article  PubMed  CAS  Google Scholar 

  125. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990;265:7709–12.

    PubMed  CAS  Google Scholar 

  126. Yeh J, Rein M, Nowak R. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril. 1991;56:997–1000.

    Article  PubMed  CAS  Google Scholar 

  127. Ren Y, Yin H, Tian R, Cui L, Zhu Y, Lin W, Tang XD, Gui Y, Zheng XL. Different effects of epidermal growth factor on smooth muscle cells derived from human myometrium and from leiomyoma. Fertil Steril. 2011;96:1015–20.

    Article  PubMed  CAS  Google Scholar 

  128. Fayed YM, Tsibris JC, Langenberg PW, Robertson AL Jr. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin. Lab Investig. 1989;60:30–7.

    PubMed  CAS  Google Scholar 

  129. Rossi MJ, Chegini N, Masterson BJ. Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology. 1992;130:1716–27.

    PubMed  CAS  Google Scholar 

  130. Shushan A, Rojansky N, Laufer N, Klein BY, Shlomai Z, Levitzki R, Hartzstark Z, Ben-Bassat H. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod. 2004;19:1957–67.

    Article  PubMed  CAS  Google Scholar 

  131. Shushan A, Ben-Bassat H, Mishani E, Laufer N, Klein BY, Rojansky N. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril. 2007;87:127–35.

    Article  PubMed  CAS  Google Scholar 

  132. Matsuo H, Kurachi O, Shimomura Y, Samoto T, Maruo T. Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology. 1999;57(Suppl 2):49–58.

    Article  PubMed  CAS  Google Scholar 

  133. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991;251:936–9.

    Article  PubMed  CAS  Google Scholar 

  134. Nishi E, Klagsbrun M. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways. Growth Factors. 2004;22:253–60.

    Article  PubMed  CAS  Google Scholar 

  135. Nowak RA. Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors. Environ Health Perspect. 2000;108(Suppl 5):849–53.

    Article  PubMed  CAS  Google Scholar 

  136. Mangrulkar RS, Ono M, Ishikawa M, Takashima S, Klagsbrun M, Nowak RA. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod. 1995;53:636–46.

    Article  PubMed  CAS  Google Scholar 

  137. Wang J, Ohara N, Takekida S, Xu Q, Maruo T. Comparative effects of heparin-binding epidermal growth factor-like growth factor on the growth of cultured human uterine leiomyoma cells and myometrial cells. Hum Reprod. 2005;20:1456–65.

    Article  PubMed  CAS  Google Scholar 

  138. Siveen KS, Prabhu K, Krishnankutty R, Kuttikrishnan S, Tsakou M, Alali FQ, Dermime S, Mohammad RM, Uddin S. Vascular endothelial growth factor (VEGF) signaling in tumour vascularization: potential and challenges. Curr Vasc Pharmacol. 2017;15:339–51.

    Article  PubMed  CAS  Google Scholar 

  139. Matsumoto K, Ema M. Roles of VEGF-A signalling in development, regeneration, and tumours. J Biochem. 2014;156:1–10.

    Article  PubMed  CAS  Google Scholar 

  140. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem. 1997;272:7151–8.

    Article  PubMed  CAS  Google Scholar 

  141. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947–54.

    PubMed  CAS  Google Scholar 

  142. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab. 1995;80:1853–8.

    PubMed  CAS  Google Scholar 

  143. Sanci M, Dikis C, Inan S, Turkoz E, Dicle N, Ispahi C. Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma. Acta Histochem. 2011;113:317–25.

    Article  PubMed  CAS  Google Scholar 

  144. Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Investig. 1997;76:245–55.

    PubMed  CAS  Google Scholar 

  145. Gentry CC, Okolo SO, Fong LF, Crow JC, Maclean AB, Perrett CW. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci (Lond). 2001;101:691–5.

    Article  CAS  Google Scholar 

  146. Hassan MH, Eyzaguirre E, Arafa HM, Hamada FM, Salama SA, Al-Hendy A. Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. Am J Obstet Gynecol. 2008;199:156.e1–8.

    Article  CAS  Google Scholar 

  147. Hong T, Shimada Y, Uchida S, Itami A, Li Z, Ding Y, Kaganoi J, Komoto I, Sakurai T, Imamura M. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med. 2001;8:141–8.

    PubMed  CAS  Google Scholar 

  148. Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM, Gliksman M, Goy A, Suh KS. Molecular and clinical significance of fibroblast growth factor 2 (FGF2/bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 2016;7:44735–62.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Fernig DG, Gallagher JT. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res. 1994;5:353–77.

    Article  PubMed  CAS  Google Scholar 

  150. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003;111:1037–54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  151. Wolanska M, Bankowski E. Fibroblast growth factors (FGF) in human myometrium and uterine leiomyomas in various stages of tumour growth. Biochimie. 2006;88:141–6.

    Article  PubMed  CAS  Google Scholar 

  152. Rauk PN, Surti U, Roberts JM, Michalopoulos G. Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells. Am J Obstet Gynecol. 1995;173:571–7.

    Article  PubMed  CAS  Google Scholar 

  153. Betsholtz C, Johnsson A, Heldin CH, Westermark B, Lind P, Urdea MS, Eddy R, Shows TB, Philpott K, Mellor AL, et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. Nature. 1986;320:695–9.

    Article  PubMed  CAS  Google Scholar 

  154. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys. 2002;398:284–90.

    Article  PubMed  CAS  Google Scholar 

  155. Liang M, Wang H, Zhang Y, Lu S, Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol Ther. 2006;5:28–33.

    Article  PubMed  CAS  Google Scholar 

  156. Boehm KD, Daimon M, Gorodeski IG, Sheean LA, Utian WH, Ilan J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev. 1990;27:93–101.

    Article  PubMed  CAS  Google Scholar 

  157. Hwu YM, Li SH, Lee RK, Tsai YH, Yeh TS, Lin SY. Increased expression of platelet-derived growth factor C messenger ribonucleic acid in uterine leiomyomata. Fertil Steril. 2008;89:468–71.

    Article  PubMed  CAS  Google Scholar 

  158. Suo G, Jiang Y, Cowan B, Wang JY. Platelet-derived growth factor C is upregulated in human uterine fibroids and regulates uterine smooth muscle cell growth. Biol Reprod. 2009;81:749–58.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  159. Taniguchi Y, Morita I, Kubota T, Murota S, Aso T. Human uterine myometrial smooth muscle cell proliferation and vascular endothelial growth-factor production in response to platelet-derived growth factor. J Endocrinol. 2001;169:79–86.

    Article  PubMed  CAS  Google Scholar 

  160. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.

    Article  PubMed  CAS  Google Scholar 

  161. Nusse R, Clevers H. Wnt/β-Catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985–99.

    Article  PubMed  CAS  Google Scholar 

  162. Tran FH, Zheng JJ. Modulating the wnt signaling pathway with small molecules. Protein Sci. 2017;26:650–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  163. Mangioni S, Viganò P, Lattuada D, Abbiati A, Vignali M, Di Blasio AM. Overexpression of the Wnt5b gene in leiomyoma cells: implications for a role of the Wnt signaling pathway in the uterine benign tumor. J Clin Endocrinol Metab. 2005;90:5349–55.

    Article  PubMed  CAS  Google Scholar 

  164. Tanwar PS, Lee HJ, Zhang L, Zukerberg LR, Taketo MM, Rueda BR, Teixeira JM. Constitutive activation of Beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod. 2009;81:545–52.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  165. Ono M, Yin P, Navarro A, Moravek MB, Coon JS V, Druschitz SA, Serna VA, Qiang W, Brooks DC, Malpani SS, Ma J, Ercan CM, Mittal N, Monsivais D, Dyson MT, Yemelyanov A, Maruyama T, Chakravarti D, Kim JJ, Kurita T, Gottardi CJ, Bulun SE. Paracrine activation of WNT/beta-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci U S A. 2013;110:17053–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Shiga University of Medical Science, Otsu, Japan

    Fuminori Kimura M.D., Ph.D., Shunichiro Tsuji M.D., Ph.D. & Takashi Murakami M.D., Ph.D.

Authors
  1. Fuminori Kimura M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shunichiro Tsuji M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Murakami M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fuminori Kimura M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan

    Norihiro Sugino

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kimura, F., Tsuji, S., Murakami, T. (2018). Molecular Pathogenesis of Uterine Fibroids. In: Sugino, N. (eds) Uterine Fibroids and Adenomyosis. Comprehensive Gynecology and Obstetrics. Springer, Singapore. https://doi.org/10.1007/978-981-10-7167-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7167-6_3

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7166-9

  • Online ISBN: 978-981-10-7167-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation